Hairy cell leukemia and COVID-19 adaptation of treatment guidelines.
Michael GreverLeslie AndritsosVersha BanerjiJacqueline C BarrientosSeema BhatJames S BlachlyTimothy CallMatthew CrossClaire DeardenJudit DemeterSascha DietrichBrunangelo FaliniFrancesco ForconiDouglas E GladstoneAlessandro GozzettiSunil IyengarJames B JohnstonGunnar JuliussonEric KrautRobert J KreitmanFrancesco LauriaGerard LozanskiSameer A ParikhJae H ParkAaron PolliackFarhad RavandiTadeusz RobakKerry A RogersAlan SavenJohn Francis SeymourTamar TadmorMartin S TallmanConstantine S TamEnrico TiacciXavier TroussardClive S ZentThorsten ZenzPier Luigi Luigi ZinzaniBernhard J WoermannPublished in: Leukemia (2021)
Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.
Keyphrases
- coronavirus disease
- sars cov
- clinical practice
- acute myeloid leukemia
- end stage renal disease
- cell therapy
- bone marrow
- newly diagnosed
- chronic kidney disease
- prognostic factors
- stem cells
- respiratory syndrome coronavirus
- early onset
- combination therapy
- peritoneal dialysis
- intellectual disability
- peripheral blood
- patient reported outcomes
- drug induced